Latest News
Hepatocellular carcinoma, a type of liver cancer, is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. Screening efforts for this cancer focus on individuals diagnosed with viral hepatitis or those known to have irreversible liver scarring, or cirrhosis. Due in part to increasing rates of obesity, another major risk factor is emerging, metabolic dysfunction-associated steatotic liver disease (MASLD), but factors associated with MASLD are not included in current screening practices.
In response, researchers at Yale have developed and validated a new risk score for hepatocellular carcinoma that considers these factors. Their work, “Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis” was published on November 6, 2024, in JAMA Network Open.
- September 10, 2024
Hepatocellular carcinoma is the most common form of liver cancer in adults. Hepatitis C infection is a known cause of hepatocellular carcinoma because the virus causes chronic inflammation and scarring of the liver, known as cirrhosis. Newer anti-viral drugs offer highly effective cures for hepatitis C, leading to stabilization of hepatitis C-related liver disease and decreased rates of hepatocellular carcinoma. Although new infections can occur at any age, the “baby boomer” generation born between 1945-1965 represents the largest population affected by hepatitis C in the United States. Yale's new research looked at whether ongoing liver cancer screening for individuals who achieved hepatitis C cure improves their overall survival rates.
- June 03, 2024
Meet Glenn Belinsky, a research associate in the Section of Digestive Diseases, who studies risk factors for Parkinson’s disease in patients with Gaucher disease.
- February 19, 2024
Yale researchers have collaborated with other experts in the field of hepatocellular carcinoma (HCC), or liver cancer, to develop the most recent American Association for the Study of Liver Diseases (AASLD) practice guidance for liver cancer.
- May 12, 2023
While a single rare disease may only affect a small proportion of the population, as many as 10 percent of Americans live with rare diseases, and most of those 30 million people have limited or no treatments and lack access to expert care. Now, Yale School of Medicine is joining the NORD Rare Disease Centers of Excellence network with a mission to provide better care for patients with large unmet needs.
- November 28, 2022
In a new paper, Pramod Mistry and colleagues describe a thriving program that provides therapies to people with rare diseases.
- June 14, 2019
Connecticut Magazine’s 2019 “Best Doctors” list includes 217 Yale Medicine physicians in 50 specialties who were selected by their peers as the best in their fields.
- April 15, 2019Source: Science Daily
Adults suffering from liver disease of unknown cause represent an understudied and underserved patient population. A new study supports the incorporation of whole-exome sequencing (WES) in the diagnosis and management of adults suffering from unexplained liver disease and underscores its value in developing an understanding of which liver phenotypes of unknown cause in adults are genetic.
- November 15, 2018
Pramod Mistry, MBBS, PhD, FRCP, professor of medicine (digestive diseases) and pediatrics; professor of cellular & molecular physiology, presented statistics, research, and patient examples in the November 15 Department of Internal Medicine’s Medical Grand Rounds: “Gaucher Disease: The Story of How a Rare Inborn Error of Metabolism Transforms our Understanding of Two Common Diseases.”